BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Furiex Pharmaceuticals, J&J deal

Johnson & Johnson's Janssen Pharmaceutica N.V. subsidiary did not exercise an option to regain rights to antibiotic candidate JNJ-Q2 from partner Furiex. According to Furiex, Janssen is focusing future R&D investment in antivirals and...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >